Key investment events: The company released its 2017 three-quarter report, and achieved operating income of 16.16 billion yuan (+58.9%) and net profit to mother of 0.41 billion yuan (+80.5%) in the first three quarters of 2017. The third quarter achieved operating income of 6.93 billion yuan (+82.04%) and net profit to mother of 0.175 billion yuan (+37.41%) in a single quarter. The rapid growth in performance is mainly due to strong execution of extended mergers and acquisitions. 1) The company achieved operating income of 16.16 billion yuan (+58.9%) and net profit of 0.41 billion yuan (+80.5%) in the first three quarters of 2017. The main reason was that mergers and acquisitions were accelerated in the context of the two-vote system. The number of unequal control deliveries completed in the first half of 2017 was 16, consolidated revenue of 1.25 billion yuan, and consolidated profit of 57.14 million yuan. Since most of the target consolidation period occurred after May, we estimate that mergers and acquisitions were postponed in the first three quarters Contributions to the company's revenue and profits increased compared to the interim report. 2) The company's net interest rate increased by 0.72 percentage points in the first three quarters. Among them, gross margin increased by 0.39 percentage points, mainly benefiting from the increase in equipment ratio; sales expenses decreased by 0.24 percentage points and management expenses decreased by 0.4 percentage points, reflecting scale effects. 3) The third quarter achieved operating income of 6.93 billion yuan (+82.04%) and net profit to mother of 0.175 billion yuan (+37.41%). The reason why the revenue growth rate was faster than the net profit growth rate of the mother was that some major mergers and acquisitions were non-wholly-owned mergers and acquisitions, and the share of minority shareholders' revenue increased 17% in 2016 Q3 to 30% in 2017 Q3. The core business is pharmaceutical distribution, which is currently undergoing rapid expansion. After divesting loss-making industrial assets in 2015-2016, the core asset was pharmaceutical circulation. The company currently covers the pharmaceutical commercial logistics network system in 11 provinces (cities) in China. The core area is Shandong, and other advantageous regions are Henan, Hubei, Xinjiang, Anhui, Shaanxi, Hunan and Heilongjiang. In 2016, 6 platform companies (provincial level) were established, and business expansion was carried out on the basis of platform companies, which is expected to enhance the company's centralized procurement bargaining capacity, warehousing and logistics allocation efficiency, and overall competitive strength in bidding within the region. The main expansion route is epitaxial mergers and acquisitions. It is estimated that there will be close to 30 mergers in 2017, mainly in regions with traditional advantages such as Beijing, Hunan, Anhui, Shandong, and Heilongjiang. In the field of pharmaceutical distribution, the company was the first company to implement GPO in the industry. Currently, Haiwang GPO is mature in operation in Shandong. GPO in Anhui is progressing, and it is expected to seize a larger market share through GPO. Entering Proton Healthcare is a scarce target for A-share high-precision medical equipment. The company partnered with Provision to advance proton therapy. ProNova, a subsidiary of Provision, can produce compact proton therapy devices using patented superconductivity technology, and the product is being approved and registered with the FDA. Provision also has a comprehensive cancer diagnosis and treatment center, and has become one of the world's leading cancer treatment centers, providing a full range of solutions for oncology treatment. According to statistics from the 21st Century Economic Report, more than 40 hospitals in China have applied for the construction of proton therapy centers. If calculated at 1.5 billion yuan per set, the domestic proton market space will reach 60 billion yuan. We believe that the company is expected to share the domestic market through joint ventures. The company is a scarce target for A-share high-precision proton therapy. Profit forecasting and valuation. We expect the company's EPS in 2017-2019 to be 0.24 yuan, 0.32 yuan, and 0.41 yuan, respectively. The corresponding PE is 26 times, 20 times, and 16 times, respectively. The valuation is relatively reasonable for a comparable company, and the first coverage gives a “gain” rating. Risk warning: Risk of epitaxial mergers and acquisitions falling short of expectations, risk of impairment of goodwill.

海王生物(000078)三季报点评:业绩表现靓丽 并购执行力强
Kaiwang Biotech (000078) Review of the Third Quarterly Report: Beautiful Performance and Strong M&A Execution
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got It
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got It
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Latest
05:18
Berkshire: Directors will no longer be eligible for re-election after their 80th birthday, but Warren Buffett is not subject to this new rule.
BRK.A+1.89%
05:16
The short-term spending bill was passed by a vote in the Senate.
05:15
The FTSE A50 index futures closed up 0.58% in consecutive overnight trading, reported at 13,819.000 points.
Investment Course

Choose stocks based on financial reports
Quickly master financial season learning guidelines
When the financial season comes, company stock prices are the most likely to rise and fall, and many excellent investors will see the financial season as a good
[2025.2] How should NVIDIA's performance be viewed? The key indicator to watch for short-term stock prices is this.
NVIDIA has been one of the best-performing Technology giants in the US stock market over the past two years, and since 2024, its stock price has experienced sig
How to view Tesla's performance in January 2025? Pay attention to these four key points.
It's earnings season for US stocks again. The performance of giant companies not only affects their own stock prices but also influences the overall trend of th
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.